Summary
The pharmacokinetics of intravenous high-dose methotrexate were studied in two groups of children being treated for malignant diseases, mostly acute lymphatic leukemia. The peak serum level of methotrexate of 2.32·10−5 mol/l was found in children given 500 mg methotrexate/m2 by a 24 h infusion, and another group given 2790 mg/m2 during a 6 h infusion had serum levels as high as 2.16·10−4 mol/l. The decay of serum concentration of methotrexate after completion of the infusion followed a diphasic curve, with an initial serum half-life of 4.8 h, followed by a second half-life of 34.4 h at distribution equilibrium. The apparent volume of distribution was 56.8 litres/m2. Significant levels of methotrexate were found in cerebrospinal fluid, but penetration into cerebrospinal fluid was slow. Urinary excretion of methotrexate was considerable. Four to five days after commencement of the infusion, urinary concentrations of methotrexate still exceeded the serum levels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bratlid, D., Bergan, T.: Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology14, 464–472 (1976)
Dahl, S. G.: Dosering av medikamenter ut fra deres distribusjons volum og biologiske halveringstid. Tidsskr. Nor. Laegeforen.94, 1208–1211 (1974)
Djerassi, I., Rominger, C. J., Kim, J. S., et al.: Phase I study of high doses of methotrexate with citrovorum factor in patient with lung cancer. Cancer30, 22–30 (1972)
Frei, E., Jaffe, N., Pitman, S.: Limitations of the methotrexate and citrovorum-factor treatment. N. Engl. J. Med.292, 107–108 (1975)
Goldie, J. H., Price, L. A., Harrap, K. R.: Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. Eur. J. Cancer8, 409–414 (1972)
Huffman, D. H., Wan, S. H., Azarnoff, D. L., Hoogstraten, B.: Pharmacokinetics of methotrexate. Clin. Pharmacol. Ther.14, 572–579 (1973)
Jaffe, N., Frei, E., Traggis, D., Bishop, Y.: Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N. Engl. J. Med.291, 994–997 (1974)
Kinkade, J. M., Vogler, W. R., Dayton, P. G.: Plasma levels of methotrexate in cancer patients as studied by an improved spectrophotofluorometric method. Biochem. Med.10, 337–350 (1974)
Lewitt, M., Mosher, M. B., DeConti, R. C., et al.: Improved therapeutic index of methotrexate with leukovorin rescue. Cancer Res.32, 1729–1734 (1973)
Pinedo, H. M., Zaharko, D. S., Bull, J. M., Chabner, B. A.: The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leukovorin and nucleosides. Cancer Res.36, 4418–4424 (1976)
Salasoo, S., Irving, M. G., Freedman, A.: Methotrexate megadose followed by folate resque. II. Clearance patterns in patients receiving sequential megadose infusions. Med. J. Aust.1, 826–828 (1976)
Shapiro, W. R., Young, D. F., Mehta, B. M.: Methotrexate: Distribution in cerebrospinal fluid after intreavenous, ventricular and lumbar injections. N. Engl. J. Med.293, 161–166 (1975)
Stoller, R. G., Jacobs, S. A., Drake, J. C., Lutz, R. J., Chabner, B. A.: Pharmacokinetics of high-dose methotrexate (NSU-740). Cancer Chemother. Rep.6, 19–24 (1975)
Wang, J. J., Freeman, A. I., Sinks, L. F.: Treatment of acute lymphocytic leukemia by high-dose intravenous methotrexat Cancer Res.36, 1441–1444 (1976)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bratlid, D., Moe, P.J. Pharmacokinetics of high-dose methotrexate treatment in children. Eur J Clin Pharmacol 14, 143–147 (1978). https://doi.org/10.1007/BF00607446
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607446